Black Diamond Therapeutics (BDTX)
(Delayed Data from NSDQ)
$5.97 USD
-0.20 (-3.24%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $5.97 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Brokerage Reports
Black Diamond Therapeutics, Inc. [BDTX]
Reports for Purchase
Showing records 81 - 87 ( 87 total )
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
BDTX-189 Phase 1 Data Slated for ASCO 2021; 3Q20 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
BDTX-189''s Selectivity Index Positions It as a Potential Best-in-Class Agent, in Our View; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
BDTX-189 Receives Fast Track Designation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
ASCO Updates - We''re Keeping a Close Eye on Amivantamab and Enhertu; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Competitive Landscape Updates at ASCO 2020; 1Q20 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Breaking the Mold in Precision Oncology; Initiating at Buy and $53 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R